What does Ancestry’s move into consumer genetics mean?
Is editing the germline inevitable and should we be focusing more on where the unmet medical need is?
Genome editing is a subject seemingly on everybody’s lips. There are some shared concerns (and some shared excitement!) over what will happen next.
Poll results and analysis. Direct-To-Consumer testing.
We take a look at some of the most frequently mentioned challenges facing pharmacogenomics today.
How much genomic data is out there at the moment, and how quickly will it increase?
We take a look at the most frequently mentioned challenges facing cancer genomics today.
Rare genetic diseases are proving to be an increasingly lucrative market for drug developers. However, it is a niche with many unique challenges to overcome.
Poll results and analysis. Bioinformaticians still a preciously limited resource.
How do can you give informed consent to share your data for research purposes, if no one knows how it might be used?
With the eruption in ‘omic’ data, there aren’t enough people with the necessary skills to translate it into applicable knowledge.